Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05535244 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Hoffmann-La Roche.

Active
Registry status
Phase 1
Development phase
90
Enrollment target
20
Study locations

NCT05535244 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 90 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05535244, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
90 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Tocilizumab
  • DRUG Cevostamab

Study Locations (20)

Other

  • UZ Leuven Gasthuisberg - Leuven
  • CHU NANTES - Hôtel Dieu - Nantes
  • APHP - Hospital Saint Louis - Paris
  • CHU de Poitiers - La Miletrie - Poitiers
  • Klinik der Uni zu Köln - Cologne
  • Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II - Hamburg
  • Universitätsklinikum Würzburg - Würzburg
  • Hadassah Ein Karem Hospital - Jerusalem
  • Sheba Medical Center - Ramat Gan
  • Sourasky Medical Centre - Tel Aviv

Colorado

  • University of Colorado - Aurora

Florida

  • Mayo Clinic-Jacksonville - Jacksonville

Maryland

  • University of Maryland Greenebaum Cancer Center - Baltimore

Massachusetts

  • Dana Farber Cancer Institute - Boston

Minnesota

  • Mayo Clinic - Rochester - Rochester

New York

  • Memorial Sloan Kettering Cancer Center - New York

Tennessee

  • Tennessee Oncology - Nashville - Nashville

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2022-10-17
Est. Completion 2027-02-26
Phase Phase 1

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05535244

The ClinicalTrials.gov registry entry for NCT05535244 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Tocilizumab is the first listed.

NCT05535244 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT05535244 about?

NCT05535244 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma". This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

What is the current status of trial NCT05535244?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2022-10-17. Estimated completion is 2027-02-26.

What conditions does trial NCT05535244 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT05535244?

The interventions under investigation include: Tocilizumab (DRUG), Cevostamab (DRUG).

Who is sponsoring clinical trial NCT05535244?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05535244 being conducted?

This trial has 20 study locations across Colorado, Florida, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.